## Jan Wehkamp

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/855898/publications.pdf

Version: 2024-02-01

106 papers 10,567 citations

50276 46 h-index 100 g-index

112 all docs

112 docs citations

times ranked

112

12109 citing authors

#	Article	IF	CITATIONS
1	Human $\hat{l}^2 \hat{a} \in d$ efensin $\hat{a} \in \mathcal{Q}$ suppresses key features of asthma in murine models of allergic airways disease. Clinical and Experimental Allergy, 2021, 51, 120-131.	2.9	19
2	Curbing gastrointestinal infections by defensin fragment modifications without harming commensal microbiota. Communications Biology, 2021, 4, 47.	4.4	4
3	Human $\hat{I}^2$ -Defensin 2 Mutations Are Associated With Asthma and Atopy in Children and Its Application Prevents Atopic Asthma in a Mouse Model. Frontiers in Immunology, 2021, 12, 636061.	4.8	12
4	Fragmentation of Human Neutrophil $\hat{l}_{\pm}$ -Defensin 4 to Combat Multidrug Resistant Bacteria. Frontiers in Microbiology, 2020, $11,1147$ .	3.5	11
5	Infodemiology of Crohn's disease and Ulcerative colitis using GoogleÂTrends – an approach to investigate patient needs. Zeitschrift Fur Gastroenterologie, 2020, 58, 224-233.	0.5	6
6	Human $\hat{l}^2$ -Defensin 2 Mediated Immune Modulation as Treatment for Experimental Colitis. Frontiers in Immunology, 2020, 11, 93.	4.8	52
7	The human α-defensin-derived peptide HD5(1–9) inhibits cellular attachment and entry of human cytomegalovirus. Antiviral Research, 2020, 177, 104779.	4.1	10
8	An Update Review on the Paneth Cell as Key to Ileal Crohn's Disease. Frontiers in Immunology, 2020, 11, 646.	4.8	63
9	Proteolytic Degradation of reduced Human Beta Defensin 1 generates a Novel Antibiotic Octapeptide. Scientific Reports, 2019, 9, 3640.	3.3	20
10	Human Paneth cell α-defensin-5 treatment reverses dyslipidemia and improves glucoregulatory capacity in diet-induced obese mice. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E42-E52.	3.5	22
11	Enterocutaneous fistula in severely active Crohn's disease: preoperative anti-TNF alpha treatment to limit bowel resectionâ€"report of a case. International Journal of Colorectal Disease, 2019, 34, 369-373.	2.2	1
12	Ustekinumab is effective in biological refractory Crohn's disease patients–regardless of approval study selection criteria. Intestinal Research, 2019, 17, 340-348.	2.6	18
13	Human Endogenous Retroviruses: Residues of Ancient Times Are Differentially Expressed in Crohn's Disease. Inflammatory Intestinal Diseases, 2018, 3, 125-137.	1.9	6
14	Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis. Inflammatory Intestinal Diseases, 2018, 3, 116-124.	1.9	20
15	Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Research, 2018, 7, 1207.	1.6	38
16	Histone deacetylase-mediated regulation of the antimicrobial peptide hBD2 differs in intestinal cell lines and cultured tissue. Scientific Reports, 2018, 8, 12886.	3.3	10
17	Coding variants in NOD-like receptors: An association study on risk and survival of colorectal cancer. PLoS ONE, 2018, 13, e0199350.	2.5	6
18	Influence of NOD2 Variants on Trichuris suis ova Treatment Outcome in Crohn's Disease. Frontiers in Pharmacology, 2018, 9, 764.	3.5	0

#	Article	IF	Citations
19	Netzbildung als Abwehrstrategie des menschlichen Körpers. BioSpektrum, 2018, 24, 146-148.	0.0	О
20	Intestinal manipulation affects mucosal antimicrobial defense in a mouse model of postoperative ileus. PLoS ONE, 2018, 13, e0195516.	2.5	14
21	$\hat{l}^2$ -Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor. Frontiers in Immunology, 2018, 9, 1735.	4.8	12
22	Low-grade appendiceal mucinous neoplasm (LAMN) – 3-year endoscopic follow-up underlines benign course ofÂLAMN type 1. Zeitschrift Fur Gastroenterologie, 2017, 55, 149-152.	0.5	5
23	Intestinal Barrier Function and the Gut Microbiome Are Differentially Affected in Mice Fed a Western-Style Diet or Drinking Water Supplemented with Fructose. Journal of Nutrition, 2017, 147, 770-780.	2.9	118
24	Microbiome and chronic inflammatory bowel diseases. Journal of Molecular Medicine, 2017, 95, 21-28.	3.9	14
25	High Demand for Psychotherapy in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1796-1802.	1.9	23
26	In the Wnt of Paneth Cells: Immune-Epithelial Crosstalk in Small Intestinal Crohn's Disease. Frontiers in Immunology, 2017, 8, 1204.	4.8	20
27	Ubiquitously expressed Human Beta Defensin 1 (hBD1) forms bacteria-entrapping nets in a redox dependent mode of action. PLoS Pathogens, 2017, 13, e1006261.	4.7	63
28	Recent advances in understanding and managing Crohn's disease. F1000Research, 2016, 5, 2896.	1.6	14
29	Inflammatory Bowel Disease: Crohn's disease and ulcerative colitis. Deutsches Ärzteblatt International, 2016, 113, 72-82.	0.9	111
30	Intestinal barrier analysis by assessment of mucins, tight junctions, and $\hat{l}_{\pm}$ -defensins in healthy C57BL/6J and BALB/cJ mice. Tissue Barriers, 2016, 4, e1208468.	3.2	40
31	Crosstalk between microbiota, pathogens and the innate immune responses. International Journal of Medical Microbiology, 2016, 306, 257-265.	3.6	34
32	Antimicrobial Peptides in the Gut. , 2016, , 67-88.		1
33	Management of Crohn's disease – are guidelines transferred to clinical practice?. United European Gastroenterology Journal, 2015, 3, 371-380.	3.8	20
34	Disulphide-reduced psoriasin is a human apoptosis-inducing broad-spectrum fungicide. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13039-13044.	7.1	67
35	Medical Therapy of Perianal Crohn's Disease. Visceral Medicine, 2015, 31, 265-272.	1.3	8
36	Crohn's disease-derived monocytes fail to induce Paneth cell defensins. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14000-14005.	7.1	71

#	Article	ΙF	Citations
37	Intestinal barrier in inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 1165.	3.3	309
38	TCF-1-mediated Wnt signaling regulates Paneth cell innate immune defense effectors HD-5 and -6: implications for Crohn's disease. American Journal of Physiology - Renal Physiology, 2014, 307, G487-G498.	3.4	41
39	Human colonic mucus is a reservoir for antimicrobial peptides. Journal of Crohn's and Colitis, 2013, 7, e652-e664.	1.3	92
40	<scp>A</scp> ntimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Molecular Medicine, 2013, 5, 1465-1483.	6.9	293
41	Inflammatory bowel disease: an impaired barrier disease. Langenbeck's Archives of Surgery, 2013, 398, 1-12.	1.9	110
42	A Peptide Derived from the Highly Conserved Protein GAPDH Is Involved in Tissue Protection by Different Antifungal Strategies and Epithelial Immunomodulation. Journal of Investigative Dermatology, 2013, 133, 144-153.	0.7	41
43	Defective Antibacterial Barrier in Inflammatory Bowel Disease. Digestive Diseases, 2013, 31, 310-316.	1.9	35
44	Antimicrobial Activity of High-Mobility-Group Box 2: a New Function to a Well-Known Protein. Antimicrobial Agents and Chemotherapy, 2013, 57, 4782-4793.	3.2	19
45	Antimicrobial Peptides and Inflammatory Bowel Disease. , 2013, , 255-273.		1
46	Bacteria Regulate Intestinal Epithelial Cell Differentiation Factors Both In Vitro and In Vivo. PLoS ONE, 2013, 8, e55620.	2.5	44
47	Gastric Antimicrobial Peptides Fail to Eradicate Helicobacter pylori Infection Due to Selective Induction and Resistance. PLoS ONE, 2013, 8, e73867.	2.5	33
48	Association of a Functional Variant in the Wnt Co-Receptor LRP6 with Early Onset Ileal Crohn's Disease. PLoS Genetics, 2012, 8, e1002523.	3.5	44
49	Bifidobacterium bifidum in a rat model of necrotizing enterocolitis: antimicrobial peptide and protein responses. Pediatric Research, 2012, 71, 546-551.	2.3	43
50	Human $\hat{I}_{\pm}$ -Defensin 6 Promotes Mucosal Innate Immunity Through Self-Assembled Peptide Nanonets. Science, 2012, 337, 477-481.	12.6	337
51	Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins. International Journal of Medical Microbiology, 2012, 302, 276-287.	3.6	40
52	More than a marine propeller – the flagellum of the probiotic Escherichia coli strain Nissle 1917 is the major adhesin mediating binding to human mucus. International Journal of Medical Microbiology, 2012, 302, 304-314.	3.6	78
53	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut, 2012, 61, 1693-1700.	12.1	1,295
54	Olfactomedin-4 is a glycoprotein secreted into mucus in active IBD. Journal of Crohn's and Colitis, 2012, 6, 425-434.	1.3	61

#	Article	IF	CITATIONS
55	Results of the 2nd Scientific Workshop of the ECCO (III): Basic mechanisms of intestinal healing. Journal of Crohn's and Colitis, 2012, 6, 373-375.	1.3	50
56	Intestinal bacterial translocation in rats with cirrhosis is related to compromised paneth cell antimicrobial host defense. Hepatology, 2012, 55, 1154-1163.	7.3	164
57	Innate immunity includes defensins. Annals of Gastroenterology, 2012, 25, 3-5.	0.6	15
58	Reduction of disulphide bonds unmasks potent antimicrobial activity of human $\hat{l}^2$ -defensin 1. Nature, 2011, 469, 419-423.	27.8	428
59	Waking the wimp: Redox-modulation activates human beta-defensin 1. Gut Microbes, 2011, 2, 262-266.	9.8	21
60	Paneth cell function - Implications in pediatric Crohn disease. Gut Microbes, 2011, 2, 47-51.	9.8	9
61	From intestinal stem cells to inflammatory bowel diseases. World Journal of Gastroenterology, 2011, 17, 3198-203.	3.3	66
62	Antimicrobial Peptides in Gastrointestinal Inflammation. International Journal of Inflammation, 2010, 2010, 1-11.	1.5	37
63	Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8772-8777.	7.1	183
64	Defective Paneth Cellâ€"Mediated Host Defense in Pediatric Ileal Crohn's Disease. American Journal of Gastroenterology, 2010, 105, 452-459.	0.4	58
65	Innate antimicrobial immunity in inflammatory bowel diseases. Expert Review of Clinical Immunology, 2010, 6, 809-818.	3.0	13
66	Paneth's disease. Journal of Crohn's and Colitis, 2010, 4, 523-531.	1.3	115
67	Innate antimicrobial host defense in small intestinal Crohn's disease. International Journal of Medical Microbiology, 2010, 300, 34-40.	3.6	47
68	Elevated Human $\hat{I}^2$ -Defensin-2 Levels Indicate an Activation of the Innate Immune System in Patients With Irritable Bowel Syndrome. American Journal of Gastroenterology, 2009, 104, 404-410.	0.4	146
69	Family history of Crohn's disease is associated with an increased risk for Crohn's disease of the pouch. Inflammatory Bowel Diseases, 2009, 15, 163-170.	1.9	46
70	Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3. Microbes and Infection, 2009, 11, 384-393.	1.9	46
71	Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation, 2009, 77, 84-94.	1.9	229
72	Genetic Variants of Wnt Transcription Factor TCF-4 (TCF7L2) Putative Promoter Region Are Associated with Small Intestinal Crohn's Disease. PLoS ONE, 2009, 4, e4496.	2.5	125

#	Article	IF	CITATIONS
73	Is there a role for defensins in IBD?. Inflammatory Bowel Diseases, 2008, 14, S85-S87.	1.9	9
74	In vivo gene expression profiling of human intestinal epithelial cells: analysis by laser microdissection of formalin fixed tissues. BMC Genomics, 2008, 9, 209.	2.8	45
75	Diminished Expression of Apical Sodium-Dependent Bile Acid Transporter in Gallstone Disease Is Independent of Ileal Inflammation. Digestion, 2008, 78, 52-59.	2.3	19
76	NOD2/CARD15 Gene Variants Are Linked to Failure of Antibiotic Treatment in Perianal Fistulating Crohn's Disease. American Journal of Gastroenterology, 2008, 103, 1197-1202.	0.4	29
77	Is there a role for defensins in IBD?. Inflammatory Bowel Diseases, 2008, 14, S85-S87.	1.9	2
78	Antimicrobial host defense in the upper gastrointestinal tract. European Journal of Gastroenterology and Hepatology, 2008, 20, 1151-1158.	1.6	23
79	Crohn's disease-Defect in innate defence. World Journal of Gastroenterology, 2008, 14, 5499.	3.3	46
80	Induction of Human $\hat{l}^2$ -Defensin 2 by the Probiotic Escherichia coli Nissle 1917 Is Mediated through Flagellin. Infection and Immunity, 2007, 75, 2399-2407.	2.2	288
81	Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut, 2007, 56, 1240-1247.	12.1	138
82	Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. Journal of Leukocyte Biology, 2007, 81, 907-915.	3.3	99
83	The Paneth Cell α-Defensin Deficiency of Ileal Crohn's Disease Is Linked to Wnt/Tcf-4. Journal of Immunology, 2007, 179, 3109-3118.	0.8	287
84	Defensins and cathelicidins in gastrointestinal infections. Current Opinion in Gastroenterology, 2007, 23, 32-38.	2.3	113
85	Defensins and other antimicrobial peptides in inflammatory bowel disease. Current Opinion in Gastroenterology, 2007, 23, 370-378.	2.3	143
86	Host–microbe interaction: mechanisms of defensin deficiency in Crohn's disease. Expert Review of Anti-Infective Therapy, 2007, 5, 1049-1057.	4.4	13
87	A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon. American Journal of Human Genetics, 2006, 79, 439-448.	6.2	487
88	Paneth cell antimicrobial peptides: Topographical distribution and quantification in human gastrointestinal tissues. FEBS Letters, 2006, 580, 5344-5350.	2.8	147
89	A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. Journal of Microbiological Methods, 2006, 65, 335-345.	1.6	77
90	Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. European Journal of Gastroenterology and Hepatology, 2006, 18, 615-621.	1.6	149

#	Article	IF	CITATIONS
91	Paneth cells and the innate immune response. Current Opinion in Gastroenterology, 2006, 22, 644-650.	2.3	39
92	A New Look at Crohn's Disease: Breakdown of the Mucosal Antibacterial Defense. Annals of the New York Academy of Sciences, 2006, 1072, 321-331.	3.8	55
93	NOD2/CARD15 Mediates Induction of the Antimicrobial Peptide Human Beta-defensin-2. Journal of Biological Chemistry, 2006, 281, 2005-2011.	3.4	288
94	Reduced Paneth cell $\hat{l}_{\pm}$ -defensins in ileal Crohn's disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18129-18134.	7.1	954
95	Mechanisms of Disease: defensins in gastrointestinal diseases. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 406-415.	1.7	137
96	NOD2 mutation and mice: no Crohn's disease but many lessons to learn. Trends in Molecular Medicine, 2005, 11, 307-309.	6.7	15
97	Human Defensins in Crohn's Disease. , 2005, 86, 42-54.		43
98	Serum Procalcitonin Differentiates Inflammatory Bowel Disease and Self-limited Colitis. Inflammatory Bowel Diseases, 2004, 10, 229-233.	1.9	34
99	NF-κB- and AP-1-Mediated Induction of Human Beta Defensin-2 in Intestinal Epithelial Cells by <i>Escherichia coli</i> Nissle 1917: a Novel Effect of a Probiotic Bacterium. Infection and Immunity, 2004, 72, 5750-5758.	2.2	437
100	Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. Journal of Leukocyte Biology, 2004, 77, 460-465.	3.3	141
101	Inducible and Constitutive $\hat{l}^2$ -Defensins Are Differentially Expressed in Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2003, 9, 215-223.	1.9	260
102	Antimicrobial Peptides in the Skin. New England Journal of Medicine, 2003, 348, 361-363.	27.0	19
103	Crohn's disease. European Journal of Gastroenterology and Hepatology, 2003, 15, 627-634.	1.6	151
104	Human $\hat{l}^2$ -defensin 2 but not $\hat{l}^2$ -defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2002, 14, 745-752.	1.6	197
105	Measurement of antimicrobial activity under reducing conditions in a modified radial diffusion assay. Protocol Exchange, 0, , .	0.3	1
106	Production of recombinant hBD-1 in Escherichia coli and its specific polyclonal antibody in rabbits. Protocol Exchange, $0$ , , .	0.3	1